LP-ACE2 treatment repaired BRB dysfunction and reduced diabetes-induced retinal inflammation, as observed by increased ZO-1 expression and reduced VCAM-1 expression and the reduced generation of acellular capillaries. Here, VCAM1 is linked to diabetes mellitus.